Virax Biolabs Group (VRAX)
Develops T-cell immune profiling for post-infection syndromes and sells research-use immune reagents.
Something off on this page? Send us feedback.
Develops the unapproved ViraxImmune platform to profile T-cell dysfunction in post-acute infection syndromes, while selling ImmuneSelect peptide pools, ELISpot plates and immune reagents for research use. Product sales fund a business still centered on clinical validation and regulatory development.
Develops ViraxImmune, a T-cell immune-profiling platform aimed initially at Long COVID, ME/CFS and post-treatment Lyme disease. The platform is intended to characterize immune dysfunction, chronic inflammation and immune exhaustion in people with persistent post-infection symptoms, while larger clinical and analytical validation remains required. Its U.S. plan begins with a laboratory-developed test and may later extend to an in-vitro diagnostic route.
Sells ImmuneSelect peptide pools, ELISpot plates and related immune reagents to research laboratories, academic institutions, biopharmaceutical companies and distributors. These products are research-use only and cannot support clinical diagnosis or patient management. Operations center on Glasgow laboratory work and a Shanghai procurement and distribution office; future ViraxImmune revenue depends on validation, regulatory status, qualified laboratories, reimbursement, manufacturing and adoption.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $6.5M · Total debt $414.4K · Total assets $8.3M · Shareholders' equity $7.6M
- Revenue
- $12.4K
- Operating income
- −$6.4M
- Net income
- −$5.0M
No dividends on record.
| Institutions3 holders · as of Mar 31, 2026 | 0.18% | 36.8K ADS | |
| Otherremainder | 99.82% | 19.89M ADS |
19.92M ADS as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count is from the company's Mar 2023 annual report; nothing newer is on file here.
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Armistice Capital, LLCInstitution | 0.18% | 878,803 ADS | 13Fas of Mar 31, 2026 |
Jump Financial, LLCInstitution | 0.01% | 40,724 ADS | 13Fas of Mar 31, 2026 |
Advisor Group Holdings, Inc.Institution | 0.00% | 20 ADS | 13Fas of Mar 31, 2026 |
James Alexander Cunliffe Foster1Insiderofficer: Chief Executive Officer | — | — | Form 4filed Mar 18, 2026 ↗ |
James FosterInsider | —24.90% of class, as filed | — | 13Gfiled Oct 29, 2025 ↗ |
- This position is filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
Nothing filed in the last 12 months.
- QIAGEN
Direct RUO overlap in SARS-CoV-2 T-cell-response assays.
- Adaptive Biotechnologies
T-cell repertoire platform for immune-profiling research.
- Abbott
Core-lab diagnostics supplier with infectious-disease assays.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Virax Biolabs Group | $2.54 | −0.78% | $475.0K | — | — | 33.9 | — |
| QIAGEN | $44.17 | +0.02% | $9.12B | 22.7 | 17.7 | 4.3 | +0.3% |
| Adaptive Biotechnologies | $24.89 | +0.93% | $3.95B | — | — | 12.8 | +21.5% |
| Abbott | $110.47 | +0.01% | $191.19B | 35.5 | 19.0 | 4.1 | +13.0% |
| Median | 29.1 | 18.4 | 4.3 | +13.0% |